{
    "nctId": "NCT00091832",
    "briefTitle": "Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer",
    "officialTitle": "A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastases, Bone Metastases in Subjects With Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 255,
    "primaryOutcomeMeasure": "Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)",
    "eligibilityCriteria": "Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma\n\n* At least one bone metastasis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}